PDX Organics

PDX Organics concentrated 86.21% of July 2026 sales in Flower, where sales rose 75.56% year over year and 71.52% month over month, while Vapor Pens held 8.38% share with a 136.95% month-over-month surge and no year-over-year read. Pre-Roll accounted for 4.86% share with an 81.00% month-over-month jump but a -11.56% year-over-year decline, and Concentrates sat at 0.54% share with -21.69% month-over-month movement and no year-over-year figure; the brand’s average price climbed 62.20% year over year to $18.13, and the Flower segment’s price averaged $19.68. This mix implies a Flower-led scale-up in Oregon that is rapidly adding Vapor Pens volume, while Pre-Roll volatility and the Concentrates pullback suggest resource prioritization toward higher-velocity inhalables.

Within Flower, a rank of 13 in Oregon combined with 86.21% category share of the brand’s sales points to mid-pack visibility where 71.52% month-over-month Flower growth can convert into rank gains if sustained, and the 136.95% month-over-month acceleration in Vapor Pens offers a second lane to diversify reach. However, the -11.56% year-over-year contraction in Pre-Roll alongside a 62.20% year-over-year price increase suggests an up-tiering strategy that may trade some value-seeking Pre-Roll buyers for higher-ticket Flower and Vapor Pens shoppers; the -21.69% month-over-month move in Concentrates reinforces a tighter focus on the two largest inhalable formats. The pattern implies positioning around premium-leaning inhalables where maintaining Flower momentum while nurturing the fast-growing Vapor Pens line can lift overall share without diluting price architecture.